Table 1.

Diagnostic characteristics of participants (N=391)

		n (%)
Pancreatic cancer		119 (30%)
	Adenocarcinoma	98 (82%)
	Pancreatic neuroendocrine tumour	9 (8%)
	Ampullary carcinoma	8 (7%)
	Adenosquamous carcinoma	3 (3%)
	Mucinous carcinoma	1 (<1%)
Other cancer		47 (12%)
	Oesophageal adenocarcinoma	12 (26%)
	Cholangiocarcinoma and gallbladder carcinoma	11 (23%)
	Duodenal adenocarcinoma	4 (9%)
	Lymphoma	7 (15%)
	Hepatic adenocarcinoma	4 (9%)
	Metastases	3 (6%)
	Colorectal adenocarcinoma	2 (4%)
	Other*	4 (9%)
Non-cancer†		225 (58%)
	Nil abnormal	35 (16%)
	Hiatus hernia	28 (12%)
	Gallstones	25 (11%)
	Gastritis, duodenitis, ulcer	22 (10%)
	Oesophagitis, Barrett's oesophagus	20 (9%)
	Upper gastrointestinal polyp	18 (8%)
	Intraductal papillary mucinous neoplasm	16 (7%)
	Hepatitis (viral and other causes)	11 (5%)
	Liver disease (non-alcoholic)	10 (4%)
	Cholecystitis	9 (4%)
	Drug reaction	9 (4%)
	Pancreatitis	9 (4%)
	Pancreatic cyst (serous cystadenoma, pseudocyst)	8 (4%)
	Diverticular disease	6 (3%)
	Gastro-oesophageal reflux disease, clinical	4 (2%)
	Alcoholic liver disease	2 (<1%)
	Other	16 (7%)

^*Breast, sarcoma, cancer of unknown primary, leukaemia (n=1 each).

^†Percentages total more than 100% because patients might have had more than one diagnosis.